CAIN CHRISTOPHER W. 4

4 · Viridian Therapeutics, Inc.\DE · Filed Jul 2, 2026

AI-generated summary of this filing

Updated Jul 2, 2026

Viridian (VRDN) Director Christopher Cain Receives Option Award

What Happened

Christopher W. Cain, a member of Viridian Therapeutics' board of directors, was granted a derivative award (option) covering 32,341 shares on July 1, 2026. The transaction is reported as an award/acquisition (code A) at $0.00 cash paid at grant; no immediate purchase or sale occurred.

Key Details

Transaction date: 2026-07-01; filing date: 2026-07-02 (timely).
Instrument: derivative award (option) covering 32,341 shares; reported price $0.00 at grant.
Vesting: the option vests in full on the earlier of (i) July 1, 2027 or (ii) Viridian’s 2027 annual meeting, subject to Cain’s continued Board service (Footnote 1).
Beneficial ownership: Cain holds the option for one or more investment vehicles managed by Fairmount Funds Management LLC and disclaims beneficial ownership; any net cash or stock from the option is turned over to the Adviser (Footnote 2).
Shares owned after transaction: not specified in this filing.

Context

This is a standard director compensation grant rather than an open-market purchase or sale; awards are common and do not by themselves signal a director buying shares outright. The award is a derivative that vests based on continued service and a date/meeting condition.

Form 4

Period: 2026-07-01

Director

Transactions

Award
Stock Option (Right to Buy)
[F1][F2]
2026-07-01+32,341→ 32,341 total(indirect: See Footnote)
Exercise: $18.48Exp: 2036-07-01→ Common Stock (32,341 underlying)

Footnotes (2)

[F1]The option vests in full upon the earlier to occur of (i) July 1, 2027 or (ii) the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service on the Board of Directors of the Issuer.
[F2]Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Signature

/s/ Jennifer Tousignant, Attorney-in-fact|2026-07-02

1 file